Free Trial

TerrAscend (OTCMKTS:TSNDF) Trading 4% Higher - What's Next?

TerrAscend logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Shares rose ~4% to $0.65 on Monday with about 417,866 shares traded, roughly 14% above the average session volume.
  • Zacks upgraded TerrAscend from "strong sell" to "hold" and the Street shows two Strong Buy ratings and one Hold, giving an overall average rating of "Buy."
  • Key fundamentals: market capitalization of $200.54M, a negative P/E (-1.59) indicating losses, and a high debt-to-equity ratio (2.42), with 50‑day and 200‑day moving averages at $0.65 and $0.69 respectively.
  • Five stocks to consider instead of TerrAscend.

TerrAscend Corp. (OTCMKTS:TSNDF - Get Free Report)'s share price traded up 4% during trading on Monday . The stock traded as high as $0.65 and last traded at $0.65. 417,866 shares traded hands during mid-day trading, an increase of 14% from the average session volume of 366,747 shares. The stock had previously closed at $0.6250.

Analysts Set New Price Targets

Separately, Zacks Research raised TerrAscend from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 10th. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy".

Get Our Latest Research Report on TSNDF

TerrAscend Stock Performance

The stock has a market capitalization of $200.54 million, a P/E ratio of -1.59 and a beta of 1.36. The company has a quick ratio of 0.95, a current ratio of 1.38 and a debt-to-equity ratio of 2.42. The business has a fifty day moving average price of $0.65 and a 200-day moving average price of $0.69.

TerrAscend Company Profile

(Get Free Report)

TerrAscend is a vertically integrated cannabis company that operates across cultivation, processing and retailing in North America. The company's business model spans seed-to-sale activities, enabling it to manage quality control, production efficiency and product innovation from its growing facilities through to its distribution networks. TerrAscend serves both adult-use and medical cannabis markets, offering a full suite of cannabis derivatives including dried flower, concentrates, vapes, edibles, tinctures and topicals.

Geographically, TerrAscend maintains operations in key regulated markets.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in TerrAscend Right Now?

Before you consider TerrAscend, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TerrAscend wasn't on the list.

While TerrAscend currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines